EP300 and glioblastoma: Treatment with the CBP/P300 inhibitor, A-485, resulted in a similar enrichment of downregulated ECM genes as observed with RelAMUT cells (Figure S1H), further supporting that acetylation of RelA is a critical regulatory posttranslational modification required for MES gene expression in GBM.